- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02164110
To Evaluate the Efficacy (Immunogenicity) and Safety of Euvichol in Healthy Adults and Children
December 4, 2014 updated by: EuBiologics Co.,Ltd
A Randomized, Single Blind, Multicenter, Therapeutic Confirmatory Study to Assess the Efficacy (Immunogenicity) and Safety of Euvichol in Healthy Adults and Children
The purpose of this study is to evaluate the efficacy (Immunogenicity) and Safety of Euvichol in Healthy Adults and Children.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
A randomized, single blind, multicenter, therapeutic confirmatory study to assess the efficacy (immunogenicity) and safety of Euvichol in healthy adults and children
Study Type
Interventional
Enrollment (Actual)
3632
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Quezon City, Philippines, 4332
- Antonio D. Ligsay, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
3 months to 38 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Written informed consent to study participation voluntarily provided by an individual or his/her legally acceptable representative.
- Age of 1 ~ 40 years
- An individual who can be followed up during the study period and is capable of complying with the study requirements.
Exclusion Criteria:
- History of hypersensitivity reactions to other preventative vaccinations.
- Immune function disorders including immunodeficiency diseases.
- An individual thought to have difficulty participating in the study due to severe chronic diseases, based on the judgment of the investigator.
- 38℃ or higher body temperature measured prior to investigational product dosing.
- Abdominal pain, nausea, vomiting, or decreased appetite within 24 hours prior to study initiation.
- Diarrhea or administration of antidiarrheal drugs or antibiotics to treat diarrhea within 1 week prior to study initiation.
- Other vaccination within 1 week prior to study initiation or planned vaccination during the study.
- Diarrhea or abdominal pain lasting 2 weeks or longer within 6 months prior to study initiation.
- Participation in another clinical trial with investigational product dosing within 1 month prior to study initiation.
- Pregnant or lactating women.
- An individual thought to have difficulty participating in the study due to other reasons, based on the judgment of the investigator
- Applicable to the Pivotal study only: history of cholera vaccinations or history of cholera.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Euvichol
|
Other Names:
|
Active Comparator: Shanchol
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy
Time Frame: 14 days after second doses
|
Proportion of subjects exhibiting 4-fold or greater rises in titers of anti-V.
cholera O1 antibody, relative to baseline
|
14 days after second doses
|
Safety
Time Frame: From first shot to 14 days after second dose
|
Type and frequency of solicited adverse event type (Day 0 ~ 6), Type and frequency of unsolicited adverse event type (Day 0 ~ Day 28)
|
From first shot to 14 days after second dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy
Time Frame: 14 days after second doses
|
1. Proportion of subjects exhibiting 4-fold or greater rises in titers of anti-V.
cholera O139 antibody, relative to baseline
|
14 days after second doses
|
Safety
Time Frame: From first shot to 14 days after second dose
|
1. Change from baseline in vital signs and physical examination
|
From first shot to 14 days after second dose
|
Efficacy
Time Frame: 14 days after second doses
|
1. Geometric Mean Titer (GMT) and Geometric Mean Ratio (GMR) as measured by each anti-V.
cholera antibody titer at Week 2 (Visit 3) after the second dose as compared to prior to investigational product dosing (Visit 1).
|
14 days after second doses
|
Safety
Time Frame: 14 days after second doses
|
1. Change from baseline in laboratory tests (hematologic test, blood chemistry test, urinalysis) to be performed only in subjects who participate in the Pivotal study.
|
14 days after second doses
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Roberto A. Espos, MD, De La Salle University Hospital Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2014
Primary Completion (Actual)
September 1, 2014
Study Completion (Actual)
October 1, 2014
Study Registration Dates
First Submitted
April 27, 2014
First Submitted That Met QC Criteria
June 12, 2014
First Posted (Estimate)
June 16, 2014
Study Record Updates
Last Update Posted (Estimate)
December 8, 2014
Last Update Submitted That Met QC Criteria
December 4, 2014
Last Verified
December 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UBC301
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prevention Harmful Effects
-
Boston Children's HospitalNational Institute on Alcohol Abuse and Alcoholism (NIAAA)CompletedPrevention Harmful EffectsUnited States
-
Karolinska InstitutetNot yet recruitingPrevention Harmful EffectsSweden
-
Zurich University of Applied SciencesUniversitat Politècnica de ValènciaCompletedPrevention Harmful Effects
-
M.D. Anderson Cancer CenterWithdrawnCancer | Prevention Harmful Effects
-
Children's Hospital of PhiladelphiaUniversity of Pennsylvania; National Institute of Nursing Research (NINR); Pennsylvania...CompletedPrevention Harmful Effects | Accidents, Traffic | Accident PreventionUnited States
-
University of MiamiNational Institutes of Health (NIH); Patricia and Phillip Frost Museum of Science... and other collaboratorsCompleted
-
Shanghai Changning Maternity & Infant Health HospitalTongji UniversityUnknown
-
University of South CarolinaCompletedPrevention Harmful EffectsUnited States
-
Tel Aviv UniversityIsrael Science FoundationCompletedPrevention Harmful EffectsIsrael
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Unknown
Clinical Trials on Euvichol
-
International Vaccine InstituteEuBiologics Co.,LtdUnknown
-
EpicentreMassachusetts General Hospital; Médecins Sans Frontières, Belgium; Ministry of...Active, not recruitingCholera | Vibrio Cholerae InfectionGuinea
-
EuBiologics Co.,LtdInstituto Universitario IVICompletedPrevention Harmful EffectsKorea, Republic of